Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Jane Street Group LLC

Jane Street Group LLC reduced its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 67.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,256 shares of the company’s stock after selling 53,404 shares during the quarter. Jane Street Group LLC’s holdings in Perspective Therapeutics were worth $337,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in CATX. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at approximately $57,000. US Bancorp DE boosted its stake in shares of Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Intech Investment Management LLC acquired a new position in Perspective Therapeutics in the 3rd quarter valued at about $137,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Perspective Therapeutics in the 3rd quarter valued at about $152,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter worth about $153,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $3.53 on Friday. Perspective Therapeutics, Inc. has a 1 year low of $2.70 and a 1 year high of $19.05. The business has a fifty day moving average of $5.33 and a 200-day moving average of $10.28.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The firm had revenue of $0.37 million during the quarter. Analysts forecast that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CATX shares. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Oppenheimer lowered their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday, November 25th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.14.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, Director Heidi Henson bought 25,975 shares of Perspective Therapeutics stock in a transaction dated Wednesday, December 4th. The stock was bought at an average price of $3.85 per share, for a total transaction of $100,003.75. Following the completion of the acquisition, the director now directly owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Johan M. Spoor purchased 8,000 shares of the stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average price of $3.77 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer now directly owns 36,257 shares of the company’s stock, valued at $136,688.89. This represents a 28.31 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 67,570 shares of company stock valued at $256,789 in the last three months. 3.52% of the stock is currently owned by corporate insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.